Sonic Healthcare Limited
SHL.AXHealthcareASXDiagnostics & Research
Scan Results
Daily timeframePart of the healthcare sector, Sonic Healthcare Limited (SHL.AX) is listed under Diagnostics & Research. With a market capitalization of $9.21B, it sits in mid-cap territory. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry.
Market Cap
$9.21B
Beta
0.57
P/E (TTM)
16.78
P/E (Fwd)
13.87
EPS (TTM)
$1.11
EPS (Fwd)
$1.34
ROE
6.6%
ROA
3.8%
Cash
$557.1M
Total Debt
$5.95B
Free CF
$597.8M
52W Change
-29.7%
Annual Financials
Cash vs Debt
On the balance sheet, SHL.AX has $557.1M in cash with $5.95B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $597.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 6.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.8% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $9.32B (2022) to $9.62B (2025).
The relatively low beta of 0.57 suggests SHL.AX is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Sonic Healthcare Limited's trajectory.